| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_96b882006e755dfc56fcabfc5fb019f6 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4525
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-107
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5383
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-438
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4525
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4525 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-107
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 |
| filingDate |
2019-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2019-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_edaa98532832c887c8e4d8dae8f4a304
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9c9470146ae3f5649c487e9a230967ee
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f64546d6b897c2f8ff61aafada478e85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d514d001ce21c69a3381f106a94164f2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_97c52bc7859a8b5d48083fef9cc6f872 |
| publicationDate |
2019-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10479797-B2 |
| titleOfInvention |
Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto |
| abstract |
The present invention relates to compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the beta-3 adrenergic receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of a beta-3 adrenergic receptor-mediated disorder, such as, heart failure; cardiac performance in heart failure; mortality, reinfarction, and/or hospitalization in connection with heart failure; acute heart failure; acute decompensated heart failure; congestive heart failure; severe congestive heart failure; organ damage associated with heart failure (e.g., kidney damage or failure, heart valve problems, heart rhythm problems, and/or liver damage); heart failure due to left ventricular dysfunction; heart failure with normal ejection fraction; cardiovascular mortality following myocardial infarction; cardiovascular mortality in patients with left ventricular failure or left ventricular dysfunction; left ventricular failure; left ventricular dysfunction; class II heart failure using the New York Heart Association (NYHA) classification system; class III heart failure using the New York Heart Association (NYHA) classification system; class IV heart failure using the New York Heart Association (NYHA) classification system; LVEF<40% by radionuclide ventriculography; LVEF≤35% by echocardiography or ventricular contrast angiography; and conditions related thereto. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11560386-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023057896-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023017388-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023026185-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10662200-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2017278102-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10927123-B2 |
| priorityDate |
2016-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |